To prevent inhibitory effects and ameliorate the exhausted phenotypes (Araki et al., 2013; Park et al., 2016), PD-1 has been disrupted in CAR T cells to improve anti-tumor efficacy and persistence (Rupp et al., 2017; Guo et al., 2018; Hu B. et al., 2019; Choi et al., 2019; Dai et al., 2019; Magnani et al., 2020; McGowan et al., 2020; Wang et al., 2021; Khan and Sarkar, 2022). This evidence concerns the gene PDCD1 and neoplasm.